Community protocol
Third-partySermorelin 5mg
- 01Reconstitution solution
- 1 mL
- 02Dose
- 0.5 mg
- 03Syringe units
- 10 units
- 04Frequency
- 7x/week
- 05Cycle length
- 90 days
- 06Bacteriostatic water
- 1 mL
- 07Bottle size
- 5 mg
- 08Bottles needed
- 9
Source note: PM dosing
Sermorelin
The shortest biologically active fragment of GHRH. Previously FDA approved as a paediatric diagnostic and therapeutic agent; withdrawn commercially, not for safety reasons.
Overview
Sermorelin is the smallest piece of natural growth hormone releasing hormone that still works — the first 29 of its 44 amino acids. It prompts the pituitary to release its own growth hormone rather than supplying growth hormone directly. Because it works through the body's normal control loop, the release stays pulsatile and feedback still applies. Its very short duration in the blood is the main practical limitation.
Sermorelin is GHRH(1-29)-NH2, the minimum sequence retaining full intrinsic activity at the GHRH receptor. Binding to the class B GPCR GHRH-R on pituitary somatotrophs activates Gs, elevating cAMP and activating PKA, which both triggers acute GH exocytosis and drives CREB-mediated Pit-1-dependent GH gene transcription. The unmodified sequence is cleaved rapidly at the Ala2-Asp3 bond by DPP-4, giving a plasma half-life of roughly 11–12 minutes. Because it acts upstream of the pituitary, IGF-1 negative feedback and somatostatin tone remain functional, and it cannot drive GH beyond the pituitary's secretory reserve — a mechanistic safety ceiling absent with exogenous recombinant GH.
Research areas
EndocrineGrowth hormone axisPaediatric growthDiagnostics
Community-specified data
Community dosage information
Not medical guidance. These third-party figures have not been independently verified, clinically reviewed, or endorsed by DB Peptide. They may be inaccurate or unsafe and should not replace product labelling or advice from a qualified clinician.
Dosing reported in the literature
Every protocol below is reproduced from a published study or approved labelling, with its source named. These are records of what was studied — not recommendations, and not a suggestion that any of them is appropriate for any person.
| Protocol as reported | Source |
|---|---|
| 0.03 mg/kg subcutaneously once daily at bedtime in paediatric growth hormone deficiencyBedtime administration aligns with the natural nocturnal GH pulse. | Geref approved labelling |
| 1 µg/kg intravenously as a single diagnostic bolusDiagnostic use only — assesses pituitary reserve, not a treatment protocol. | GHRH stimulation test protocol |
Trial status
Approved historically. Controlled trials completed in paediatric growth hormone deficiency and in adult GH axis diagnostics. No modern phase 3 programme in adults.
Registration trials
CompletedControlled trials in children with growth hormone deficiency demonstrated increased growth velocity, supporting FDA approval as Geref.
Diagnostic use
CompletedEstablished as a provocative agent for assessing pituitary somatotroph reserve, often combined with arginine.
Adult efficacy trials
NoneNo modern adequately powered trial evaluating adult body composition or ageing endpoints has been published.
Reported safety signals
- Injection site flushing, pain and swelling were the most common adverse events in registration trials.
- Because the compound cannot drive GH beyond pituitary secretory capacity, supraphysiologic GH exposure is mechanistically constrained.
- Anti-sermorelin antibodies were detected in a minority of paediatric patients on long-term use without a consistent loss of effect.
Primary sources
Medical disclaimer
This page is for informational and research purposes only. Nothing here constitutes medical advice. The compounds discussed are research chemicals. Consult a qualified clinician before starting any protocol.
How this profile was built →